Celgene Wins One Bull, Loses Another On Revlimid Potential
May 23, 2018 at 09:34 AM EDT
Celgene Corporation (NASDAQ: CELG) is down about 35 percent year-over-year, and as management resists challenges to critical Revlimid ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|